我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

卵圆孔未闭合并不明原因脑卒中的药物治疗

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第3期
页码:
284-287
栏目:
出版日期:
2013-06-25

文章信息/Info

Title:
Drug therapy of patent foramen ovale with cryptogenic stroke
作者:
何 璐; 张玉顺
(西安交通大学第一附属医院心内二科，陕西 西安 710061)
Author(s):
HE Lu;  ZHANG Yushun
(Second Department of Cardiology, First Affiliated Hospital, Medical College, Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China)
关键词:
卵圆孔未闭; 不明原因脑卒中; 治疗; 药物
Keywords:
patent foramen ovale;  cryptogenic stroke ; treatment;  drug
分类号:
R541
DOI:
-
文献标识码:
A
摘要:
目的:卵圆孔未闭（patent foramen ovale，PFO）是一种先天性心脏病变，超过25%的成人均存在PFO。PFO可能与多种病理情况有关，包括不明原因脑卒中（cryptogenic stroke，CS）、斜卧呼吸-直立型低氧血症、减压病、偏头痛等，其诊断、评估和治疗已经越来越引起人们的重视。但是，有关其治疗方法的选择目前仍在争议中，虽然尚未得到美国食品和药物管理局（FDA）的批准，经导管封堵PFO的方法在继续。其潜在的并发症包括封堵器表面血栓形成，术后房颤、残余分流，封堵器侵蚀或穿孔等。鉴于PFO封堵术与任何心脏干预一样可能引起极严重的并发症，药物治疗似乎是安全、有效的选择。本文主要综述了PFO并发CS的药物治疗，旨在为临床医生对PFO并发CS的药物选择提供理论依据。
Abstract:
AIM:Patent foramen ovale (PFO) is a congenital cardiac lesion which is present in over 25% of the adult population. The diagnosis, evaluation and treatment of PFO have attracted increasing interest as it has been suggested that PFO may be associated with various pathologic conditions, such as cryptogenic stroke, platypneaorthodeoxia syndrome, decompression sickness and migraine. The management of PFO remains controversial and though not yet approved by the U.S. Food and Drug Administration, transcatheter approach to PFO closure continues to develop but its potential complications include device embolization, thrombus formation, atrial arrhythmias, residual shunting and device erosion or perforation. Just as any cardiac intervention, transcatheter closure may cause serious complications and drug therapy thus seems to be a safe and effective option. This paper reviews the drug therapy of PFO with cryptogenic stroke to provide a theoretical basis of its drug treatment for clinicians.

参考文献/References

[1]Hagen PT,Scholz DG,Edwards WD.Incidence and size of patent foramen ovale during the first 10 decades of life:an autopsy study of 965 normal hearts[J].Mayo Clin Proc,1984,59(1):17-20.
[2]Furlan AJ,Reisman M,Massaro J,et al.Closure or medical therapy for cryptogenic stroke with patent foramen ovale[J].N Engl J Med,2012,366(11):991-999.
[3]Carroll JD,Saver JL,Thaler DE,et al.Closure of patent foramen ovale versus medical therapy after cryptogenic stroke[J].N Engl J Med,2013,368(12):1092-1100.
[4]Meier B,Kalesan B,Mattle HP,et al.Percutaneous closure of patent foramen ovale in cryptogenic embolism[J].N Engl J Med,2013,368(12):1083-1091.
[5]Homma S,Sacco RL.Patent foramen ovale and stroke[J].Circulation,2005,112(7):1063-1072.
[6]Mohr JP,Thompson JL,Lazar RM,et al.comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke[J].N Engl J Med,2001,345(20):1444-1451.
[7]Bogousslavsky J,Garazi S,Jeanrenaud X,et al.Stroke recurrence in patients with patent foramen ovale:the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group[J].Neurology,1996,46(5):1301-1305.
[8]Homma S,Sacco RL,Di Tullio MR,et al.Effect of medical treatment in stroke patients with patent foramen ovale:patent foramen ovale in Cryptogenic Stroke Study[J].Circulation,2002,105(22):2625-2631.
[9]Cujec B,Mainra R,Johnson DH.Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks[J].Can J Cardiol,1999,15(1):57-64.
[10]Mas JL,Arquizan C,Lamy C,et al.Recurrent cerebrovascular events associated with patent foramen ovale,atrial septal aneurysm, or both[J].N Engl J Med,2001,345(24):1740-1746.
[11]Sacco RL,Adams R,Albers G,et al.Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention:the American Academy of Neurology affirms the value of this guideline[J].Circulation, 2006,113(10):e409-e449.
[12]Albers GW,Amarenco P,Easton JD,et al.Antithrombotic and thrombolytic therapy for ischemic stroke:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):483S-512S.
[13]Messe SR,Silverman IE,Kizer JR,et al.Practice parameter:recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology[J].Neurology,2004,63(11):2198-2199.
[14]Kizer JR,Devereux RB.Clinical practice.Patent foramen ovale in young adults with unexplained stroke[J].N Engl J Med,2005,353(22):2361-2372.

备注/Memo

备注/Memo:
收稿日期：2013-03-27.
通讯作者：张玉顺，主任医师，主要从事先天性心脏病介入治疗研究Email:zys2889@sina.com
作者简介：何璐，住院医师，硕士Email：helu123.student@sina.com
更新日期/Last Update: 2013-07-16